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Introduction
Neuroblastoma (NB) is the most common extracranial solid neoplasma in children under 5 years of age. Despite available therapies, patients with high-risk disease present an overall survival rate lower than 50% (Maris et al., 2007) . Chemotherapeutic drugs used for high-risk NB therapy include platinum compounds, alkylating agents, topoisomerase II inhibitor, anthracycline antibiotics and vinca alkaloids (VAs), among others (George et al., 2010) . VAs, such as vincristine (VCR) and vinblastine (VBL) are antimitotic drugs that disrupt microtubule stability and induce cell death (Jordan et al., 1991) . VAs bind to important compounds of the cytoskeleton, such as β -tubulin subunits of α /β-tubulin heterodimers (Don et al., 2004) . At micromolar concentrations, VAs depolymerize microtubules, disrupt mitotic spindles, induce formation of tubulin paracrystals and G2/M block occurs (Jordan et al., 1992; Pourroy et al., 2004) . However, at nanomolar concentrations, microtubule dynamics is suppressed with no effect on microtubule depolymerization, being a postmitotic G1 arrest identified (Pourroy et al., 2004) . Both treatment with micro-and treatment with nanomolar concentrations lead to apoptosis. The mechanism by which VAs induce apoptosis is complex, involving protein kinase signaling pathways (Fan et al., 2001) , and also mitochondria also seem to play a key role in this process (Groninger et al., 2002) .
Despite the therapeutic efficacy of VAs, disadvantages have been associated with the use of these drugs in NB therapy in humans. VAs lead to toxicity (e.g. neurotoxicity (greater for VCR), bone marrow suppression (greater for VBL), and vascular complication) (Doll et al., 1986; Lobert et al., 1998) and development of resistance (Don et al., 2004) . The development of resistance towards VAs might be due to the altered expression of the neuronal-associated microtubule protein class III β -tubulin (Don et al., 2004) . The increased expression of PThis article has not been copyedited and formatted. The final version may differ from this version.
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Downloaded from JPET #188813 6 glycoprotein, a multidrug resistance protein, has also been detected in NB cells treated with VAs and may be related to resistance to VA treatment as well (Burkhart et al., 2001) . To overcome these disadvantages, efforts have been made to find more specific therapies and the combination of low doses of VAs with other compounds, such as rapamycin, is also under investigation (Bostrom et al., 1984; Marimpietri et al., 2007) .
Several molecular targets have been proposed for NB therapy (George et al., 2010; Wagner and Danks, 2009 ). These targets play crucial roles in at least one of the tumorigenic processes, such as proliferation, angiogenesis, invasion and/or metastasis. We have recently
proposed Doublecortin-like kinase (DCLK) as a novel molecular target for NB therapy (Verissimo et al., 2010) . The DCLK gene encodes for several proteins, including the microtubule-associated proteins (MAPs) doublecortin-like (DCL) and DCLK-long (Vreugdenhil et al., 2007) . These MAPs are highly expressed in neuroblasts (Shu et al., 2006; Vreugdenhil et al., 2007) and NB tumors (Verissimo et al., 2010) . They are known to regulate neurogenesis, neural migration and transport along microtubules (Fitzsimons et al., 2008; Koizumi et al., 2006; Shu et al., 2006; Vreugdenhil et al., 2007) . We, and others, have shown that DCLK-derived MAPs are involved in microtubule stabilization and regulation of mitotic spindle formation (Shu et al., 2006; Vreugdenhil et al., 2007) . It has been proposed that the mechanism of stabilization of microtubules by DCLK-derived MAPs is similar to the highly homologous MAP doublecortin (DCX) (Shu et al., 2006) . MAPs of the DCX family have homologous microtubule-binding domains (DC domains) involved in tubulin polymerization and microtubule bundling (Cierpicki et al., 2006) . The interaction of DC domains with microtubules is regulated by phosphorylation and de-phosphorylation (LoTurco, 2004) .
This article has not been copyedited and formatted. The final version may differ from this version. We, and others, have shown the essential role of DCLK in proliferation and survival of neuroblast cells. Knockdown of DCL/DCLK-long results in mitotic spindle disruption and cell cycle arrest (Shu et al., 2006; Vreugdenhil et al., 2007) . Moreover, we recently demonstrated that silencing of DCLK-derived MAPs induces apoptosis in NB cells (Verissimo et al., 2010) . Gene expression profiling revealed that genes related to oxidative stress and oxidative phosphorylation were differently expressed after knockdown of MAPs encoded by DCLK gene, and mitochondria were the most affected cellular components (Verissimo et al., 2010) .
Since both silencing of DCLK and VAs result in disruption of mitotic spindles and induction of apoptosis in NB cells, we hypothesized that they may synergize each other's effects.
Our results indeed show that there is a synergetic effect resulting in a significantly lower dose of VAs required for the induction of caspase-dependent apoptosis in NB cells.
Materials and methods
Reagents and antibodies. Vincristine (VCR) and vinblastine (VBL) were obtained from Sigma-Aldrich Chemie B.V (Zwijndrecht, The Netherlands). VBL and VCR were dissolved in ultra-purified water (Milli-Q, Millipore, the Netherlands) to 10 mg/ml stock and stored at 4ºC or -20ºC, respectively. At the time of use, VCR and VBL were freshly diluted in culture medium.
The mouse monoclonal antibody against α -tubulin was obtained from Sigma-Aldrich Chemie B.V (Zwijndrecht, The Netherlands), the secondary antibody anti-mouse-HRP from Tube-bio B.V. (Bevelandseweg, The Netherlands), the goat anti-mouse IgG conjugated to Alexa fluor 594 dye was purchased from Molecular Probes (Leiden, The Netherlands), and the anti-rabbit-HRP from Santa Cruz (Tebu-Bio, Heerhugowaard, The Netherlands). We also used a recently developed primary rabbit antibody targeting the QRDLYRPLSSDDLDSVG-C sequence, which This article has not been copyedited and formatted. The final version may differ from this version. (Zwijndrecht, The Netherlands). 5 mg/ml MTT in phosphate-buffered saline (PBS) was freshly prepared before each determination. Annexin V-Alexa 488 was prepared as previously described . The caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp(O-Met) fluoromethyl ketone (z-VAD-fmk) was purchased from Bachem CH (Weil am Rhein, Germany), the caspase substrate Ac-DEVD-AMC was obtained from Enzo Life Science (Raamsdonksveer,
The Netherlands) and 7-amido-4-methylcoumarin (AMC) from Invitrogen (Breda, The Netherlands).
Cell culture, transfection and drug treatment. Human SH-SY5Y and mouse N1E-115 neuroblastoma cells were cultured as previously described (Molenaar et al., 2008; Vreugdenhil et al., 2007) . For microscopy assays, both cell lines were grown at 70% confluence in 24-well plates with glass bottom or 96-well μ clear black plates (Greiner Bio-One BV, Alphen aan den Rijn, The Netherlands) coated with 100 ng/μl poly-L-lysine for N1E-115 or 100 μ g/ml poly-Dlysine for SH-SY5Y cells. SH-SY5Y and N1E-115 cells were transfected with specific siRNAs against DCLK-derived MAPs, as previously described (Verissimo et al., 2010; Vreugdenhil et al., 2007) . N1E-115 cells were transfected with synthetic RNA oligonucleotides siDCL-2 (CAAGAAGACGGCUCACUCCTT-sense and 5′-GGAGUGAGCCGUCUUCUUGTTantisense) or siDCL-3 (GAAAGCCAAGAAGGUUCGATT-sense and TCGAACCUUCUUGGCUUUCTT-antisense) obtained from Eurogentec Nederland B.V.
(Maastricht, The Netherlands) (Vreugdenhil et al., 2007) . SH-SY5Y neuroblastoma cells were transfected with siDCLK-4 (GCCCACUGCAGCUUCUACCTT-sense and GGUAGAAGCUGCAGUGGGCTT-antisense) or siDCLK-5 JPET #188813 9 (UGGAGUACACCAAGAAUGTT-sense and CAUUCUUGGUGUACUCCATT-antisense) siRNAs purchased from Qiagen (Venlo, The Netherlands) (Verissimo et al., 2010) . Here, when
we mention DCLK knockdown, we are referring to silencing of DCLK-derived MAPs. SH-SY5Y cells were transfected with 50, 100, 200 or 400 nM of siDCLK-4 or siDCLK-5 siRNAs (Verissimo et al., 2010) and N1E-115 cells were transfected with 12.5, 25, 50 or 100 nM of siDCL-2 or siDCL-3 siRNAs (Vreugdenhil et al., 2007) . Transfection was performed using Neuroblatoma doxycycline-inducible stable cell lines. The development of the NB doxycycline-inducible stable cell lines from N1E-115 was described by Verissimo et al. 2010 (Verissimo et al., 2010 . In the presence of doxycycline (Dox), the cells express a shRNA against DCLK-derived MAP DCL. The sequence of the shRNA expressed in shDCL-2 cell line is 5'-ACAAGAUGCAGGAUGACCAGC-3' and the shDCL-3 cell line expresses the shRNA with the sequence 5'-ACAACAAGAUGCAGGAUGACC-3'. As negative control cell line we used the RNA isolation. Cells were harvested and the RNA was isolated using TRIzol reagent (Invitrogen BV) according to the manufacturer's specifications. The RNA concentration and purity were determined using a NanoDrop spectrophotometer (NanoDrop products, Wilmington, DE).
Quantitative real-time PCR. Quantitative real-time PCR (RT-qPCR) was performed using ABI Prism 7900HT Sequence Detection system (Applied Biosystems, Foster City, CA)
according to the manufacturer's instructions. RT-qPCR was carried out with a target-specific assay (Assays-on-demand Gene expression system; Applied Biosystems). Messenger RNA expression of ATP5e (Mm00445969_m1) and Ndufa2 (Mm00477755_g1), were analyzed. The expression levels were normalized to 18S rRNA (Hs99999901_s1, Applied Biosystems).
Western blot analysis. Protein lysates, SDS-PAGE, and western blotting were performed as previously described (Vreugdenhil et al., 2007) . DCL expression was normalized to α -tubulin. Analysis and quantification of the relative optical densities were performed using ImageJ software (Abramoff et al., 2004 (Jordan et al., 1992; Muller et al., 1990 propidium iodide (red), resulting in a yellow fluorescence. We performed differential interference contrast (DIC) and fluorescence imaging on a Nikon TE-2000 E system under controlled conditions (37ºC, 5% CO 2 ). Five images were taken per well with two wells used per treatment and two independent experiments were performed. Image analysis and cell counting were performed using ImageJ software (Abramoff et al., 2004) .
MTT assay. The effects of DCLK knockdown and VCR or VBL on cell proliferation and survival were determined using the colorimetric MTT assays described by Mosmann (Mosmann, 1983 ) with some modifications. Both N1E-115 and SH-SY5Y cell lines were seeded in 96-well culture plates at a seeding density of 6000 and 10000 cells/well, respectively. N1E-115 cells were used as negative control. DIC and fluorescence imaging were performed using BD Pathway TM 855 imager (Becton Dickinson) under controlled conditions (37ºC, 5% CO 2 ).
Quantitative image analysis was performed as described before . The total fluorescent intensity per image and the total cell area were quantified using Image Pro (Media Cybernetics, Bethesda, MD). compound in a synergistic combination that can be reduced at a certain effect level when compared with the doses of each treatment alone (Chou and Talalay, 1984) .
Caspase-3 activity assay. We performed a caspase-3 activity assay as previously described (Qin et al., 2011) Antwerpen, Belgium). 10 units/ml purified caspase-8 enzyme (#BML-SE172, Enzo Life Sciences, Antwerpen, Belgium) was used as positive control. After 30 minutes incubation, caspase-8 activity was assessed using Centro XS 3 Microplate Luminometer LB 960 (Berthold Technologies, Vilvoorde, Belgium) and results were normalized to total amount of protein, which was determined using the Pierce BCA protein assay (Thermo Fisher Scientific, Landsmeer, The Netherlands). Two independent experiments were performed.
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Results
Combined DCLK knockdown and treatment with VAs potentiates microtubule disruption. We first investigated the effect of the combined treatment with VAs (VCR or VBL) and DCLK knockdown (VCR + DCLK KD or VBL + DCLK KD) on the microtubule network ( Fig. 1) . In NB cells transfected with a non-targeting siRNA (negative control, NC) and treated with the vehicle used to dissolve VAs, a normal arrangement and organization of the microtubule network was observed (Fig. 1A) . Mitotic cells also presented a normal phenotype. In HeLa cells, treatment with VBL doses higher than 10 μ M results in the formation of tubulin paracrystals (Jordan et al., 1992 tubulin paracrystals and cells became rounded (Fig. 1, B and E). Similar results were obtained using 50 μ M VCR (Fig. 1, B and F). Cell rounding was also observed in cells transfected with previously described siRNAs targeting DCLK (Vreugdenhil et al., 2007) , siDCL-2 or siDCL-3 alone (Fig. 1, C and D) . In these cells, the microtubules looked less organized as compared to NB cells transfected with negative control siRNA (Fig. 1A) . Additionally, in mitotic cells the morphology of the mitotic spindles was altered, being in line with previous results (Shu et al., 2006; Vreugdenhil et al., 2007) . Tubulin paracrystals were not found in cells treated with siRNAs alone and no differences were found between cells transfected with siDCL-2 or with siDCL-3 alone (Fig. 1 , B-D). In the combined treatment groups (VBL + siDCL-2, VBL + siDCL-3, VCR + siDCL-2 or VCR + siDCL-3), we detected that the microtubules were reduced to small globular paracrystals in around 40 % of the cells and the other cells presented tubulin paracystals (Fig. 1, B and G-J). The observed and registered cells that were under combined treatment showed higher disruption of microtubules compared with cells incubated with VAs (VCR or VBL) or DCLK knockdown (siDCL-2 or siDCL-3 transfection) alone. A similar phenotype, microtubules reduced to small globular paracrystals, was detected by Jordan et al. in HeLa cells treated with 100 μ M VBL (Jordan et al., 1992) . We did not detect significant differences between VCR + DCLK KD and VBL + DCLK KD (Fig. 1, B and G-J). with non-targeting siRNA (NC) and non-transfected cells (Supplemental Fig. 1 ). We found that the concentration of VCR needed to induce cell death in N1E-115 cells can be reduced significantly (p < 0.001) in cells transfected with siDCL-2 (5.6 fold reduction) or siDCL-3 (7.3 fold reduction) (Fig. 2, A and B ; Table 1 ). The effect of the combination with VBL was even more pronounced: a significant (p < 0.001) 21.1 fold reduction was found when co-treated with siDCL-2 and a 12.5 fold reduction when co-treated with si-DCL-3. In SH-SY5Y human NB cells, we observed a significant (p < 0.001) though less pronounced difference in EC50 values between VCR treated cells with siDCLK-4 (2.09 fold reduction) and siDCLK-5 (3.47 fold reduction) compared with the negative control ( Table 2) . Although a reduction of EC50 for VBL treatment with both siDCLK-4 and siDCLK-5 was detected, no significant difference was obtained when compared to VBL with non-targeting siRNA (VBL + NC) treatment.
Combination of DCLK knockdown with VAs increases cell death in NB cells
The effect of VAs + DCLK KD was further investigated for a possible synergistic effect.
For this study, we treated the cells for 15 hours with different doses of VCR or VBL and different concentrations of siRNAs as described in the Material and Methods section. Fig. 3 shows that the different concentrations of siRNA induced different levels of DCLK knockdown, as measured by western blot analysis. No significant difference in DCLK expression was detected between cells transfected with different concentrations of NC siRNA (12.5, 25, 50 and 100 nM), cells with mock transfection (treated with lipofectamine only) and no treated cells (Supplemental Fig. 2 ). The determination of siRNA doses was based on results obtained previously, which demonstrated that 50 nM and 200 nM siRNA was enough to induce significant knockdown in N1E-115 and SH-SY5Y cells, respectively (Verissimo et al., 2010) . Since the present ( Fig. 1 and 2 ; Table 1 and 2) and previous studies (Verissimo et al., 2010) show no significant differences between the two siRNAs used to induce DCLK knockdown in N1E-115
This article has not been copyedited and formatted. The final version may differ from this version. We investigated the effect of the different combined treatments on cell proliferation and induction of cell death using the MTT assay (Mosmann, 1983) . The data was analyzed by means of CalcuSyn software (Chou and Talalay, 1984) . This software provided combined index (CI)
values based on multi-drug dose-effect calculations using the median method, as described in
Material and Methods section. Synergism (CI lower than 1) was observed with all combined treatments, except with the combination of 50 nM siDCLK-4 and 0.1 μ M VBL in SH-SY5Y cells (Table 3 ). In N1E-115 cells, synergism was detected even at 12.5 nM, which already induces 43.08 ± 3.32 % DCLK knockdown (Fig. 3) . In SH-SY5Y, synergism was consistently detected at higher doses of siRNA and VAs than in N1E-115 cells (Table 3) .
We also determined the dose-reduction index (DRI), which estimates how much the dose of VAs or siRNAs can be reduced by the combined treatment (Table 3 ). In N1E-115 cells, the DRI of VCR ranges from 1.6 to 4.6 and of VBL from 5.1 to 146.4. In SH-SY5Y, DRI analysis indicated that the concentration of VCR and VBL could be reduced 86.8 and 14.8 times, respectively, when 10 μ M of the VA was combined with 200 nM of siDCLK-4 (Table 3 ). As indicated in Table 3 , the combined treatment would allow the reduction of siRNAs concentration as well. The DRI of siDCL-3 ranges from 1.9 to 8.0 and the DRI of siDCLK-4 is between 1.7 and 15.1.
The synergistic effect of DCLK knockdown and VAs involves an apoptosis pathway.
To explore if the cells die via an apoptotic process, as previously observed with independent DCLK knockdown (Verissimo et al., 2010) and VAs (Marimpietri et al., 2007; Pourroy et al., 2004) , we performed four different apoptotic assays ( Fig. 4 and 5 ; Supplemental Fig. 3 ). N1E- Methods section and studied with time-lapse imaging of phosphatidylserine translocation (Fig. 4 and Supplemental Movie) and a TUNEL-based assay (Supplemental Fig. 3 and Supplemental Table 2 ). Time-lapse imaging of phosphatidylserine translocation allowed us to detect the progression of the apoptotic process in real time . After automated imaging, quantitative analysis was performed. Two-way ANOVA showed a highly significant As expected, the caspase inhibitor z-VAD-fmk inhibited the apoptotic process induced by VAs (VCR or VBL) + DCLK KD (Fig. 4, B-D) . Since z-VAD-fmk reacts on other enzymatic systems, experiments where the observed effects may be attributed to inhibition of caspases as those described herein should be interpreted carefully (Misaghi et al., 2006) . We observed significant differences (p < 0.05) between VA and VA + DCLK knockdown at different VA (VCR or VBL) doses (Fig. 4, C and D) . The exception was 0.01 μ M VBL (the lowest dose tested) combined with DCLK silencing, which was not significantly different (p = 0.2608) from cells treated with 0.01 μ M VBL alone (Fig. 4D) .
We calculated multi-drug dose effects to determine if there was synergism between the effect of DCLK knockdown and VAs (VCR or VBL) treatment in the induction of apoptosis. As shown in Supplemental Table 1 Table 1 ).
The occurrence of a synergistic apoptotic effect was further investigated using a TUNELbased assay (Supplemental Table 2 ). We determined the percentage of TUNEL-positive cells for the different conditions (different doses of siDCL-3, VAs and the combination of those).
Subsequently, we calculated the combined index (CI) using CalcuSyn software (Chou and Talalay, 1984) . We obtained CI values lower than 1 for the combination of siDCL-3 and VAs, This article has not been copyedited and formatted. The final version may differ from this version. plus VAs (Supplemental Fig. 3 ). This suggests that the detected TUNEL-positive cells were indeed apoptotic cells.
Combining DCLK knockdown with VAs induces apoptosis via caspase-3 and
caspase-8 activation. We performed a modified caspase-3 activity assay in which the caspase-3-like activity was measured by monitoring the production of cleaved fluorescent AMC from a caspase-3 substrate Ac-DEVD-AMC in extracts of treated N1E-115 NB cells (Lazebnik et al., 1994) . The study of caspase-8 activity allowed us to investigate if an extrinsic apoptotic pathway is involved the synergistic apoptotic process in NB cells treated with VAs (VCR or VBL) and DCLK knockdown.
N1E-115 NB cells were treated separately or in combination with different concentrations of VAs (VCR or VBL) and DCLK knockdown (siDCL-3 transfection). A nontargeting siRNA was used as negative control (NC) for transfection (see Material and Methods section). As in non-transfected cells (data not shown), no caspase-3 activity was detected in cells transfected with NC siRNA (Fig. 5 ). Cells treated with a combination of VAs and siDCL-3 presented a significantly higher caspase-3 activity than cells treated with VAs or siDCL-3 alone (Fig. 5) . The synergistic effect was not significant in cells treated with 0.01 μ M VCR, the lowest VAs concentration we tested (Fig. 5A) . The caspase-3 activity was mostly enhanced (p < 0.01) by combining DCLK knockdown in the treatment when cells were treated with 0.1 μ M VAs or 1 μ M VCR (Fig. 5, A and B) . The increase of caspase-3 activity after the combined treatment was DCLK silencing induces changes in mitochondria activity. We have previously found a high correlation between the expression of DCL and mitochondria-related genes, such as genes involved in the oxidative phosphorilation process (Verissimo et al., 2010) . Since changes in mitochondria activity due to DCLK knockdown might contribute to the synergistic apoptotic process detected with the combined treatment (DCLK KD + VAs), we have explored the effect of DCLK silencing on mitochondria activity. We checked the mRNA expression levels of two genes, NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 (Ndufa2) and ATP synthase subunit epsilon (ATP5e), which play a crucial role on the oxidative phosphorylation process (Fig. 6A ). In addition, we investigated the effect on ATP synthesis (Fig. 6B ). We detected a significant decrease (p<0.001) in the expression of both genes when DCLK is silenced compared to cells that express DCLK (Fig. 6A) . In agreement, less ATP synthesis was measured in the neuroblastoma cells with DCLK knockdown (Fig. 6B) . We detected an ATP reduction of 
Discussion
In the current study we investigated the effect of combining VAs treatment and DCLK knockdown in NB cells. We showed that the combined treatment results in a strong synergistic effect inducing NB cell death. Moreover, we demonstrated that the NB cells die via a caspase-3-dependent apoptosis process. Therefore, this study indicates that the combined treatments tested in this work permit a significant reduction in VAs doses required to effectively kill neuroblastoma cells in vitro.
VAs are important chemotherapeutic agents used in NB therapy. However, there is evidence that treatment of NB with VAs results in toxicity (Lobert et al., 1998) and in the development of drug resistance (Don et al., 2004) . Therefore, the reduction of the dose of these compounds is desired. It has been shown that combining VAs with other drugs is more effective than single-drug treatment allowing a significant reduction of the doses (Marimpietri et al., 2005) . The combined treatment might prevent the activation of compensatory pathways by NB cells, allowing a higher efficiency of the treatment (Petrelli and Giordano, 2008 ).
Here we investigate the combination of the VAs treatment with knocking down of the microtubule-stabilizing proteins encoded by DCLK gene by RNA interference technology. The novelty of this combined treatment has several aspects: 1) Since both DCLK silencing (Shu et al., 2006; Vreugdenhil et al., 2007) and VAs (Jordan and Wilson, 2004) destabilization, one would expect an additive or synergistic apoptotic effect from the combined treatment; 2) In case of synergistic effect, a significant reduction of the compounds may be used and therefore a more specific and less toxic therapeutic approach might be obtained; 3) Since VAs lead to the development of drug resistance through an increase of microtubule-stabilizing proteins (Don et al., 2004; Lobert et al., 1998) , silencing the DCLK might allow that NB cells become more vulnerable and therefore less resistant to treatment with VAs; 4) DCLK-derived
MAPs are quite specifically expressed in neuroblasts (Vreugdenhil et al., 2007) and highly expressed in human NBs (Verissimo et al., 2010) ; 5) Silencing of DCLK leads to disruption of mitotic spindles and induces apoptosis (Shu et al., 2006; Verissimo et al., 2010; Vreugdenhil et al., 2007) . Therefore, the combined VAs + DCLK KD approach might be more effective than pre-existing approaches for NB.
Our data indicate that silencing the expression of DCLK sensitizes NB cells for microtubules-destabilizing agents VCR and VBL. This sensitizing effect was more effective in N1E-115 than in SH-SY5Y NB cells. This difference might be due to the fact that the SH-SY5Y cell line also expresses DCX, which may compensate for the silencing of DCLK (Verissimo et al., 2010) . Such compensating effects between DCX and DCLK have been described (Deuel et al., 2006; Koizumi et al., 2006) . Future studies are needed to investigate whether or not the expression of DCX in SH-SY5Y compensates for DCLK knockdown and provides resistance of these cells towards VAs. An alternative explanation might be related to the achieved knockdown levels of DCLK, as higher concentration of siRNAs had to be used to obtain knockdown in SH-SY5Y than in N1E-115 cells.
We identified synergism in the inhibition of proliferation and induction of N1E-115 NB cell death by combining DCLK silencing and VAs. Moreover, our results suggest that the combined treatment-induced cell death is mediated via a caspase-3-dependent apoptotic process.
In line with this notion are the findings that microtubule-destabilizing agents, such as VAs, cause activation of caspase-3 (Fan et al., 2001 ) and silencing of DCLK leads to activation of caspase-3 as well (Verissimo et al., 2010) . Previous studies have shown that VAs induce caspase-8 activation (Bayless and Davis, 2004; Casado-Zapico et al., 2010) . We have detected an increase in caspase-8 activity in NB cells treated with the combination of VAs and DCLK knockdown compared to cells treated with VAs alone. The apoptotic mechanism induced by VAs has also been related with mitochondria activity (Moon and Lerner, 2002) with up-regulation of the proapoptotic Bax and inactivation of anti-apoptotic Bcl-2. In WSU-CLL cells, VCR and VBL induced Bcl2 phosphorylation (Moon and Lerner, 2002) . DCLK knockdown leads to activation of the intrinsic apoptotic process in NB cells as well, with up-regulation of Bax and downregulation of Bcl2 (Verissimo et al., 2010) . Therefore, our results suggest that the combined treatment results in activation of an extrinsic (caspase-8) apoptotic pathway that converges with the intrinsic (mitochondrial) apoptotic pathway at caspase-3.
The synergistic effect between VAs and siRNAs that target DCLK might be related to their distinct and independent effects on the spindle-microtubules, the changes on the oxidative phosphorylation process, and induction of apoptosis. Therefore, when these compounds are combined, a stronger induction of apoptotic cell death may be obtained than by either compound alone. In Fig. 7 we propose a hypothetical model for the consequences of the combined treatment that result in a synergistic apoptotic effect.
VAs bind to β -tubulin subunits of the α /β-tubulin heterodimers, affecting the polymerization, stabilization and dynamics of the microtubules (Fig. 7) . High-and low-affinity VAs-binding sites in the microtubules have also been found (Mollinedo and Gajate, 2003) . At low concentrations, VAs bind at the plus (+) ends of (spindle) microtubules, thereby inhibiting tubulin dimer addition. At high concentrations, VAs are able to bind in addition to the lowaffinity sites along the walls of the microtubules, resulting in the separation of the protofilaments and formation of paracrystalline structures (Mollinedo and Gajate, 2003) . Treatment with VAs leads to the disruption of microtubules, particularly spindle microtubules, resulting in slowing or blocking of cell-cycle at metaphase-anaphase transition and induction of apoptosis (Jordan and Wilson, 2004) . The mitotic arrest at low concentrations is due to alterations in microtubule dynamics rather than microtubule depolymerization (Jordan and Wilson, 2004) . We detected less synergism at higher concentrations of VAs, probably due to the distinct action of these agents at different concentrations. At high doses, the induction of apoptosis might also occur without cellcycle arrest (Pourroy et al., 2004) .
Silencing of DCLK results in disruption of the spindle microtubules (Shu et al., 2006; Vreugdenhil et al., 2007) . The stabilization of the microtubules and regulation of mitotic spindle formation by DCLK might be similar to the homologue DCX (Shu et al., 2006) . DCLK, like DCX, has two microtubule-binding domains (DC-domains) and a Ser/Pro-rich region (Vreugdenhil et al., 2007) . Each DC-domain binds tubulin and microtubules in a different way (Kim et al., 2003) . Since one DC-domain interacts with tubulin dimers and the other domain the microtubule, a stabilizing role for DC-containing proteins in microtubule nucleation has been suggested (Kim et al., 2003) . DCX selectively binds 13 protofilament microtubules over a fenestration in the microtubule wall and it interacts with four tubulin monomers (Moores et al., 2004) . Hence, it has the potential to reinforce the lateral connections between protofilaments and to enhance longitudinal interactions, which is an outstanding way for crosslinking protofilaments and increasing microtubule stability (Moores et al., 2004) . Thus, silencing of DCLK may result JPET #188813 27 in a destabilized (spindle) microtubule organization that facilitates the access of VAs to the microtubules, leading to an effective microtubule disruption at low doses of VAs. In other words, the effect of the combined treatment may converge at the disruption of (spindle) microtubules and, subsequently, apoptosis (Fig. 7) .
Silencing of DCLK resulted in down-regulation in the expression of oxidative phosphorylation genes and reduction of ATP synthesis. In line with this finding, we have previously described a high correlation between DCLK expression and mitochondria-related genes in NB tumors (Verissimo et al., 2010) . It is known that the disruption of the electron transport, oxidative phosphorylation, and adenosine triphosphate (ATP) production can induce apoptotic cell death (Green and Reed, 1998) . However, ATP is also required for downstream events of the apoptotic process (Green and Reed, 1998) .
There are similarities in the mechanism of apoptosis induction by VAs and DCLK knockdown, which might work in a synergistic manner. Both, silencing of DCLK and VAs result in cell-cycle arrest (Jordan et al., 1992; Pourroy et al., 2004; Shu et al., 2006) in changes in mitochondria activity and in apoptosis (Groninger et al., 2002; Moon and Lerner, 2002; Verissimo et al., 2010) .
In this study we show for the first time that combining DCLK silencing and VAs induces a possibly synergistic apoptotic effect in NB cells in vitro. Future in vivo studies are needed to confirm the efficacy of the combined treatment and to establish its significance as potential therapeutic approach.
In summary, the silencing of DCLK, which is highly expressed in human neuroblastomas spindles. The consequences of the combined treatment converge at the disruption of the microtubule spindles and changes in the mitochondria activity, leading to a synergistic caspasedependent apoptosis process. This figure is based on our results and on the following literature: (Cierpicki et al., 2006; Jordan et al., 1992; Jordan and Wilson, 2004; Moores et al., 2004; Pourroy et al., 2004; Shu et al., 2006; Verissimo et al., 2010; Vreugdenhil et al., 2007) .
This article has not been copyedited and formatted. The final version may differ from this version. (Chou and Talalay, 1984) . CI can be <1, =1 and >1 indicating synergism, additive effect and antagonism, respectively. DRI corresponds to how much the dose of each compound in a synergetic combination can be reduced at a certain effect compared with the doses of each compound alone (Chou and Talalay, 1984) .
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